NovaBridge Biosciences NBP
NASDAQ NBP
$0.86 +0.00 (+0.10%)
At close: Nov 11, 2026 · 4:00 PM EST

NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023)

Updated

NovaBridge Biosciences (NBP) posted Liabilities from Discontinued Operations of $50.98 million for Q4 2023.

Analysis

NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 NovaBridge Biosciences 99.23 Mn -696.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 50.98 Mn
API Access

NovaBridge Biosciences Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=NBP&period=max&api_key=YOUR_API_KEY